Philadelphia Business Journal by John George, Senior Reporter
Tuesday, November 13, 2012
Nuron Biotech Inc. said Tuesday it has completed enrollment of 500 patients for a pivotal phase-III study evaluating the safety and effectiveness of the company’s experimental multiple sclerosis treatment.
Phase-III studies are typically the last hurdle a drug developer must clear before seeking approval for a new drug candidate.
Nuron, an Exton, Pa., specialty biologics and vaccines company, is developing NU100 to treat relapsing remitting multiple sclerosis.
Shankar Musunuri, the company’s founder and CEO, said it expects to complete the study in late 2013.
The company hopes to use the results of the study to support the filing of a European marketing authorization application.
Source: BizJournals
..
If you would like, you can comment to our blog posts
LIKE this Blog by clicking the LIKE button – top left
REMAIN up to date with MS News and Education
Visit: www.msviewsandnews.org to register
.
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews
